Nephrol Dial Transplant (2001) 16: 16-18
© 2001 European Renal Association-European Dialysis and Transplant Association
The CREATE trial—building the evidence
Charité, Campus Virchow Klinikum, Humboldt-Universität, Berlin, Germany
Renal anaemia is an independent risk factor for the development of left ventricular hypertrophy (LVH), heart failure and mortality. Studies show that partial correction of anaemia leads to partial regression of LVH. However, early initiation of anaemia therapy may be the optimal way to reduce cardiac morbidity and mortality. The Cardiovascular risk Reduction by Early Anemia Treatment with Epoetin Beta (CREATE) trial will investigate the effect of early anaemia correction on cardiovascular risk reduction in patients not yet on renal replacement therapy. The primary objectives of this open, randomized, multicentre trial are to investigate the effect of early anaemia correction on the change in left ventricular mass index after 1 year, and the time to first cardiovascular event. The trial comprises two treatment arms: early intervention where patients will receive epoetin beta when their haemoglobin (Hb) level is 11–12.5 g/dl and their target Hb will be 13–15 g/dl, and late intervention, where patients will receive epoetin beta once their Hb level is <10.5 g/dl and their target Hb will be 10.5–11.5 g/dl. The study will be event-driven with a continuous evaluation and an interim analysis once every year. The inclusion of 600 patients is based on assumption of a 15–20% event rate in the control group and that 200 events are needed to detect a reduction of about one-third. In conclusion, the CREATE trial will examine whether early anaemia treatment will prevent development of LVH, reduce cardiovascular morbidity and provide other benefits.
Keywords: anaemia; epoetin beta; left ventricular hypertrophy; pre-dialysis; progressive renal insufficiency
* On behalf of the steering committee of the CREATE trial: N. Clyne, T. Drüeke, K.-U. Eckardt, F. Locatelli, I. Macdougall, F. Valderrábano and D. Tsakiris.
Correspondence and offprint requests to: Professor Kai-Uwe Klinik mit Schwerpunkt Nephrologie und Intensivmedizin, Charité, Campus Virchow-Klinikum, Universitätsklinikum der Humboldt-Universität, Augustenburger Platz 1, 13353 Berlin, Germany.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. Husemann, M. Fobker, M. Pohlen, C. Bruch, M. Hausberg, G. Breithardt, and H. Reinecke Impact of haemoglobin concentration and chronic kidney disease in patients with coronary heart disease undergoing percutaneous coronary interventions Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2563 - 2570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. W. M. Saweirs and J. Goddard What are the best treatments for early chronic kidney disease?: A Background Paper prepared for the UK Consensus Conference on Early Chronic Kidney Disease Nephrol. Dial. Transplant., September 1, 2007; 22(suppl_9): ix31 - ix38. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gilmartin Pharmacist's role in managing anemia in patients with chronic kidney disease: Potential clinical and economic benefits Am. J. Health Syst. Pharm., July 1, 2007; 64(13_Supplement_8): S15 - S22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J Smith, A. J Bleyer, W. C Little, and D. C Sane The cardiovascular effects of erythropoietin Cardiovasc Res, September 1, 2003; 59(3): 538 - 548. [Abstract] [Full Text] [PDF]
|
|